keratin associated protein 9-12, pseudogeneGenealiases: []
Q-omics provides the consensus-scored KRTAP9-12P profile across patient tissues and cancer cell-line models. KRTAP9-12P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, KRTAP9-12P is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, KRTAP9-12P RNA expression shows 6,471 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, HNSC, and STAD as cancer lineages where KRTAP9-12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP9-12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP9-12P survival associations across molecular data types. KRTAP9-12P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP9-12P RNA expression–survival associations across cancer types. High KRTAP9-12P expression shows unfavorable associations in THYM, LIHC, KICH, KIRC and HNSC, but favorable associations in UCS. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for KRTAP9-12P RNA expression.
This table summarizes KRTAP9-12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP9-12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP9-12P shows higher tumor expression in HNSC, LUAD and PRAD. The HNSC box plot shows higher KRTAP9-12P RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .039).
This table shows molecular features associated with KRTAP9-12P in patient tissues and cancer cell lines. In patient samples, KRTAP9-12P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
